Robert I Haddad

21PUBLICATIONS
175CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Mar 12, 2026
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study.

Lisa Licitra, Makoto Tahara, Kevin Harrington

|Dec 23, 2025
Automated Lymph Node and Extranodal Extension Assessment Improves Risk Stratification in Oropharyngeal Carcinoma.

Zezhong Ye, Reza Mojahed-Yazdi, Anna Zapaishchykova

|Dec 22, 2025
INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.

Danny Rischin, Aaron R Hansen, Ezra E W Cohen

|Oct 09, 2025
Elraglusib, a Glycogen Synthase Kinase 3β Inhibitor, plus Chemotherapy with or without Immunotherapy in Patients with Recurrent, Metastatic Salivary Gland Carcinoma.

Glenn J Hanna, Nicole Scarfo, Kee-Young Shin

|Sep 03, 2025
Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study.

Jean Bourhis, Lisa F Licitra, Barbara Burtness

|Jun 13, 2025
LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC.

Jean-Pascal Machiels, Jérôme Fayette, Robert Haddad

Pageof 4

Frequent Collaborators

8 joint publications

Lisa Licitra

8 joint publications

Kevin J Harrington

7 joint publications

Makoto Tahara

6 joint publications

Robert L Ferris